Respirology

Evusheld: first product approved for pre-exposure prophylaxis of COVID-19
Tixagevimab and cilgavimab are long-acting monoclonal antibodies given by intramuscular injection.
Individualizing Allergic Rhinitis Management: Focus on Speed and Efficacy
Current allergic rhinitis guidelines recommend a detailed history for patients with AR symptoms. This is crucial for determining the most appropriate treatment plan. Although there are several components to assess, it can be promptly done in-person or virtually using the acronym SPEED.
Sponsored

Aspirin beneficial to hospitalized COVID-19 patients

Even though many getting Aspirin were more likely to have other risk factors.
Updated edition of the Canadian Tuberculosis Standards is now available

Provides practical information on all aspects of tuberculosis (TB) in Canada, including epidemiology, transmission, diagnosis and management.
Pfizer COVID-19 vaccine 'grey-cap' vials that do not require dilution coming soon

Health Canada has approved an alternative to the original Pfizer COVID-19 vaccine “purple-cap” vials, for individuals 12 years of age or older.
An overview of Covifenz: The first plant-based COVID-19 vaccine approved in Canada

NACI suggests that, like Nuvaxovid, Covifenz may be an option for people unable or unwilling to receive an mRNA COVID-19 vaccine.
Patients worried about COVID risk and travel? CATMAT issues guidance statement

Travel may increase the risk of COVID-19, even while following recommended precautions.
Effectiveness of COVID-19 vaccines and booster dose against the Omicron variant

Study examines effectiveness after two doses of Pfizer, AstraZeneca or Moderna vaccine and after a booster dose with Pfizer, AstraZeneca or Moderna vaccine.
Single-dose Janssen COVID-19 vaccine less effective than two-dose Pfizer vaccine

French study compares effectiveness of Janssen vaccine versus Pfizer vaccine against COVID-19–related hospitalization.
Health Canada considering Evusheld for COVID-19 pre-exposure prophylaxis

Single doses of tixagevimab and cilgavimab reduce incidence of symptomatic COVID-19 in at-risk adults for a six-month period.

Evusheld: first product approved for pre-exposure prophylaxis of COVID-19

Individualizing Allergic Rhinitis Management: Focus on Speed and Efficacy

Aspirin beneficial to hospitalized COVID-19 patients

Updated edition of the Canadian Tuberculosis Standards is now available

Pfizer COVID-19 vaccine 'grey-cap' vials that do not require dilution coming soon

An overview of Covifenz: The first plant-based COVID-19 vaccine approved in Canada

Patients worried about COVID risk and travel? CATMAT issues guidance statement

Effectiveness of COVID-19 vaccines and booster dose against the Omicron variant

Single-dose Janssen COVID-19 vaccine less effective than two-dose Pfizer vaccine

Health Canada considering Evusheld for COVID-19 pre-exposure prophylaxis